Silvercrest Asset Management Group LLC Sells 306 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Silvercrest Asset Management Group LLC trimmed its holdings in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 7.9% during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 3,571 shares of the medical equipment provider’s stock after selling 306 shares during the period. Silvercrest Asset Management Group LLC’s holdings in Zimmer Biomet were worth $471,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Price T Rowe Associates Inc. MD raised its position in shares of Zimmer Biomet by 12.9% during the first quarter. Price T Rowe Associates Inc. MD now owns 10,642,801 shares of the medical equipment provider’s stock worth $1,404,638,000 after purchasing an additional 1,215,935 shares during the period. Primecap Management Co. CA raised its position in shares of Zimmer Biomet by 10.5% during the fourth quarter. Primecap Management Co. CA now owns 5,086,578 shares of the medical equipment provider’s stock worth $619,037,000 after purchasing an additional 484,151 shares during the period. Victory Capital Management Inc. raised its position in shares of Zimmer Biomet by 3.9% during the fourth quarter. Victory Capital Management Inc. now owns 3,199,302 shares of the medical equipment provider’s stock worth $389,355,000 after purchasing an additional 118,839 shares during the period. Van ECK Associates Corp raised its position in shares of Zimmer Biomet by 11.3% during the first quarter. Van ECK Associates Corp now owns 3,158,560 shares of the medical equipment provider’s stock worth $416,866,000 after purchasing an additional 320,002 shares during the period. Finally, Allspring Global Investments Holdings LLC raised its position in shares of Zimmer Biomet by 16.3% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 2,760,021 shares of the medical equipment provider’s stock worth $335,895,000 after purchasing an additional 386,019 shares during the period. 88.89% of the stock is currently owned by institutional investors.

Zimmer Biomet Stock Down 0.0 %

Shares of NYSE ZBH opened at $111.35 on Thursday. Zimmer Biomet Holdings, Inc. has a 52 week low of $102.00 and a 52 week high of $139.31. The business has a 50-day simple moving average of $109.96 and a two-hundred day simple moving average of $119.28. The company has a quick ratio of 0.80, a current ratio of 1.66 and a debt-to-equity ratio of 0.38. The company has a market cap of $22.91 billion, a P/E ratio of 24.10, a P/E/G ratio of 2.00 and a beta of 1.01.

Zimmer Biomet (NYSE:ZBH) last issued its earnings results on Thursday, May 2nd. The medical equipment provider reported $1.94 EPS for the quarter, topping the consensus estimate of $1.87 by $0.07. Zimmer Biomet had a return on equity of 12.70% and a net margin of 12.93%. The business had revenue of $1.89 billion during the quarter, compared to the consensus estimate of $1.87 billion. During the same quarter last year, the company earned $1.89 EPS. The firm’s revenue was up 3.2% compared to the same quarter last year. Research analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.1 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Wednesday, July 31st. Shareholders of record on Wednesday, June 26th were paid a $0.24 dividend. The ex-dividend date of this dividend was Wednesday, June 26th. This represents a $0.96 annualized dividend and a yield of 0.86%. Zimmer Biomet’s dividend payout ratio is currently 20.78%.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on the company. Morgan Stanley lowered their target price on Zimmer Biomet from $130.00 to $120.00 and set an “equal weight” rating on the stock in a research report on Monday, July 15th. Evercore ISI lowered their price target on Zimmer Biomet from $130.00 to $115.00 and set an “in-line” rating for the company in a research report on Tuesday, July 2nd. Truist Financial lowered their price target on Zimmer Biomet from $130.00 to $117.00 and set a “hold” rating for the company in a research report on Tuesday, July 16th. Citigroup lowered their price target on Zimmer Biomet from $134.00 to $120.00 and set a “neutral” rating for the company in a research report on Wednesday, July 10th. Finally, The Goldman Sachs Group assumed coverage on Zimmer Biomet in a research report on Thursday, May 30th. They set a “neutral” rating and a $129.00 target price for the company. One investment analyst has rated the stock with a sell rating, ten have given a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $129.53.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.